Glioma patients with high expressions of METTL3, IGF2BP2, VEGFA, TIMP1, HES1, COL18A1, TK1, CENPK, DNAJB11, NASP, and U2AF2 had a shorter overall survival, while glioma patients with high expressions of PHLPP2, ATP6V1A, and DLL3 showed a good overall survival, indicating that these genes could serve as prognostic markers for overall survival in glioma patients. This evidence concerns the gene HES1 and central nervous system cancer.